The identified DryNB included seven genes (KIF2C, CCNA2, NDC80, KIF11, KIF23, ANLN and CENPM) that were significantly associated with drug sensitivity or resistance of glioma patients to the targeted therapies. This evidence concerns the gene CCNA2 and central nervous system cancer.